GlassScriptPhysician profile
Jusong Choi
NPI 1811403124
$7,699.06
in general payments reported to CMS, 2019-2025
24 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.51 · 2022: $138 · 2023: $1,011 · 2024: $5,132 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,956 · Consulting Fee: $3,200 · Education: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,955.62 |
| Consulting Fee | $3,200.00 |
| Education | $392.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,702.57 | 2024-2025 | Krystexxa, Tavneos, Aranesp |
| Calliditas Therapeutics US INC. | $2,253.15 | 2023-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $350.48 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $325.04 | 2023-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $312.66 | 2023-2025 | Jynarque, Voyxact |
| Alexion Pharmaceuticals, INC. | $310.27 | 2023-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $307.10 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $264.77 | 2022-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $147.39 | 2024-2025 | |
| Horizon Therapeutics Plc | $120.72 | 2023 | Krystexxa |
| Novo Nordisk INC | $101.14 | 2024 | |
| Vifor Pharma, INC. | $89.83 | 2024-2025 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.36 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $72.76 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $48.70 | 2024 | Benlysta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $40.68 | 2025 | Terlivaz, Acthar |
| Baxter Healthcare | $29.88 | 2023 | Renal - Pd |
| Boston Scientific Corporation | $29.32 | 2025 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $27.60 | 2023 | Onpattro |
| Ani Pharmaceuticals, INC. | $22.97 | 2025 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $20.09 | 2024 | Rayaldee |
| Scpharmaceuticals INC. | $18.33 | 2025 | |
| Apellis Pharmaceuticals, INC. | $15.74 | 2025 | Empaveli |
| Abbvie INC. | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jusong Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.